Anticipation has turned to tension. The companies that own SGLT-2 and DPP-2 combination therapies are facing hardships ahead of their post-marketing surveillance period expiry.

At the diabetes expert meeting that was held by the Health Insurance Review and Assessment Service in September, the members concluded that the authorities should integrate and accept reimbursement of 2-drug and 3-drug combinations that use DPP-4 inhibitors with SGLT-2 inhibitors. The conclusion harbored industry hopes of being granted reimbursement listing for their non-reimbursed combinations.

However, no progress has been made since in extending the insurance benefits to the combinations so far, putting pressur